StocksFundsScreenerSectorsWatchlists
JAZZ

JAZZ - Jazz Pharmaceuticals PLC Stock Price, Fair Value and News

110.99USD+0.41 (+0.37%)Market Closed

Market Summary

JAZZ
USD110.99+0.41
Market Closed
0.37%

JAZZ Alerts

  • 1 major insider sales recently.

JAZZ Stock Price

View Fullscreen

JAZZ RSI Chart

JAZZ Valuation

Market Cap

6.9B

Price/Earnings (Trailing)

16.68

Price/Sales (Trailing)

1.8

EV/EBITDA

15.91

Price/Free Cashflow

6.48

JAZZ Price/Sales (Trailing)

JAZZ Profitability

EBT Margin

7.77%

Return on Equity

11.1%

Return on Assets

3.64%

Free Cashflow Yield

15.43%

JAZZ Fundamentals

JAZZ Revenue

Revenue (TTM)

3.8B

Rev. Growth (Yr)

4.1%

Rev. Growth (Qtr)

4.09%

JAZZ Earnings

Earnings (TTM)

414.8M

Earnings Growth (Yr)

139.11%

Earnings Growth (Qtr)

-35.87%

Breaking Down JAZZ Revenue

Last 7 days

-3.6%

Last 30 days

-8.2%

Last 90 days

-6.8%

Trailing 12 Months

-23.7%

How does JAZZ drawdown profile look like?

JAZZ Financial Health

Current Ratio

2.24

Debt/Equity

1.37

Debt/Cashflow

0.21

JAZZ Investor Care

Buy Backs (1Y)

1.56%

Diluted EPS (TTM)

6.12

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20233.7B3.8B3.8B3.8B
20223.3B3.5B3.6B3.7B
20212.4B2.6B2.9B3.1B
20202.2B2.2B2.3B2.4B
20192.0B2.0B2.1B2.2B
20181.7B1.8B1.9B1.9B
20171.5B1.5B1.6B1.6B
20161.4B1.4B1.4B1.5B
20151.2B1.3B1.3B1.3B
2014923.1M1.0B1.1B1.2B
2013679.7M763.7M820.4M872.4M
2012323.9M383.6M485.8M586.0M
2011272.3M272.3M272.3M272.3M
2010164.4M200.4M236.3M272.3M
2009000128.4M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Jazz Pharmaceuticals PLC

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 05, 2024
gala renee d
sold (taxes)
-200,005
115
-1,736
president & coo
Mar 07, 2024
carr patricia
sold
-206,821
116
-1,768
svp, chief accounting officer
Mar 06, 2024
carr patricia
sold
-231,628
119
-1,936
svp, chief accounting officer
Mar 05, 2024
patil neena m
sold (taxes)
-403,363
117
-3,432
evp & chief legal officer
Mar 05, 2024
cozadd bruce c
sold (taxes)
-2,636,900
117
-22,436
chairman & ceo
Mar 05, 2024
pearce samantha
sold (taxes)
-290,769
117
-2,474
svp, head of europe & internat
Mar 05, 2024
iannone robert
sold (taxes)
-504,674
117
-4,294
evp, global head of r&d
Mar 05, 2024
gala renee d
sold (taxes)
-425,694
117
-3,622
president & coo
Mar 01, 2024
carr patricia
acquired
-
-
2,987
svp, chief accounting officer
Mar 01, 2024
kennedy patrick
acquired
-
-
1,423
-

1–10 of 50

Which funds bought or sold JAZZ recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 12, 2024
FCF Advisors LLC
sold off
-100
-523,242
-
-%
Apr 12, 2024
AdvisorNet Financial, Inc
reduced
-71.43
-620
241
-%
Apr 12, 2024
FIRST FINANCIAL CORP /IN/
new
-
2,649
2,649
-%
Apr 12, 2024
GATEWAY INVESTMENT ADVISERS LLC
reduced
-1.92
-10,708
258,662
-%
Apr 12, 2024
Financial Synergies Wealth Advisors, Inc.
reduced
-40.00
-871
723
-%
Apr 12, 2024
ARGA Investment Management, LP
unchanged
-
-9,144
426,768
0.01%
Apr 11, 2024
Radnor Capital Management, LLC
unchanged
-
-21,000
989,000
0.17%
Apr 11, 2024
Cooper Financial Group
added
1.36
-3,761
485,533
0.08%
Apr 11, 2024
SANDERS MORRIS HARRIS LLC
unchanged
-
-16,573
433,512
0.08%
Apr 11, 2024
Gulf International Bank (UK) Ltd
unchanged
-
-13,000
636,000
0.02%

1–10 of 50

Are Funds Buying or Selling JAZZ?

Are funds buying JAZZ calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own JAZZ
No. of Funds

Unveiling Jazz Pharmaceuticals PLC's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
10.11%
6,363,748
SC 13G/A
Jan 24, 2024
blackrock inc.
11.2%
7,055,747
SC 13G/A
Sep 11, 2023
vanguard group inc
10.26%
6,479,474
SC 13G/A
Feb 09, 2023
vanguard group inc
9.61%
6,050,625
SC 13G/A
Jan 26, 2023
blackrock inc.
10.6%
6,652,382
SC 13G/A
Jan 20, 2023
blackrock inc.
10.6%
6,652,382
SC 13G
Jan 05, 2023
jpmorgan chase & co
4.6%
2,924,604
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Jan 28, 2022
blackrock inc.
10.5%
6,450,368
SC 13G/A
Jan 24, 2022
jpmorgan chase & co
5.2%
3,248,156
SC 13G

Recent SEC filings of Jazz Pharmaceuticals PLC

View All Filings
Date Filed Form Type Document
Apr 09, 2024
4
Insider Trading
Mar 08, 2024
4
Insider Trading
Mar 07, 2024
144
Notice of Insider Sale Intent
Mar 07, 2024
4
Insider Trading
Mar 07, 2024
4
Insider Trading
Mar 07, 2024
4
Insider Trading
Mar 07, 2024
4
Insider Trading
Mar 07, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading
Mar 05, 2024
4
Insider Trading

Peers (Alternatives to Jazz Pharmaceuticals PLC)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
39.7B
6.8B
0.01% -33.89%
-8.42
5.79
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
18.6B
1.8B
-1.06% -27.57%
-42.25
10.17
76.23% 61.08%
17.3B
2.4B
9.12% -7.56%
103
7.14
15.42% 18.43%
12.0B
3.7B
-8.48% -28.30%
20.07
3.25
8.87% 75.42%
MID-CAP
6.2B
396.6M
-9.27% -36.41%
-11.74
15.65
425.83% 18.94%
4.5B
-
-6.46% 74.90%
-6.94
60.35
54.84% -34.79%
3.2B
270.6M
-9.62% -0.34%
-13.52
11.95
440.80% -27.84%
3.0B
240.7M
-15.06% -21.14%
-10.03
12.36
-1.03% -92.09%
2.8B
726.4M
-8.60% -6.11%
-45.41
3.83
40.45% 71.62%
SMALL-CAP
1.8B
398.2M
-4.17% -12.95%
25.42
4.56
85.90% -14.05%
576.6M
983.7M
-22.12% -55.02%
-1.06
0.59
-50.36% 17.16%
448.6M
881.7K
-2.13% 345.78%
-10.06
466.16
-77.61% -5.33%
256.8M
4.9M
2.33% 7.75%
-1.9
52.78
-54.97% 51.72%
6.7M
2.1M
82.86% 81.13%
-0.25
2.14
-13.45% 66.37%

Jazz Pharmaceuticals PLC News

Latest updates
Defense World18 hours ago
Simply Wall St18 Feb 202408:00 am

Jazz Pharmaceuticals PLC Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue4.1%1,012972957893972941933814897838752608666601562535582538534508476
Costs and Expenses11.2%8898008007671,236916847726847810821445492405364724520405330374291
Operating Expenses---------------------291
  S&GA Expenses28.5%396308341298383358366309398364429261247207191208214179176168162
  R&D Expenses-----------------97.0080.0062.0060.0057.00
EBITDA Margin-0.17*-0.01*-0.01*-0.02*0.03*0.02*-0.02*0.02*0.05*0.14*0.28*0.14*--------
Income Taxes29.9%-33.10-47.20-24.32-15.30-100-43.00-16.111.00-12.46-18.0622918.0011.0019.0055.00-51.29-34.5311.00-78.6529.005.00
Earnings Before Taxes-38.2%62.0010082.0055.00-339-60.1321.006.00-44.83-67.63-136136145168171-20941.00114184115165
EBT Margin384.6%0.08*-0.03*-0.07*-0.09*-0.10*-0.02*-0.02*-0.07*-0.04*0.03*0.12*0.25*---------
Net Income-35.9%94.0014710469.00-240-19.6535.002.00-35.35-52.83-363122133148115-15774.0010226285.00159
Net Income Margin413.4%0.11*0.02*-0.02*-0.04*-0.06*-0.01*-0.01*-0.14*-0.11*-0.06*0.02*0.21*---------
Free Cashflow-48.1%15730329131733342329119716826635.00283---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets1.7%11,39311,20411,26111,04710,83510,38511,20011,76912,29912,47813,2136,7566,5366,2926,0675,2155,5395,5285,4895,2805,203
  Current Assets5.8%3,4353,2463,0102,7852,6062,5722,5912,5012,6112,6282,9543,1672,8402,5562,3021,5181,6301,5211,3701,3061,234
    Cash Equivalents12.8%1,5061,3361,2821,1688818397114915916728912,0981,058742786702637795638547310
  Inventory-2.4%5976126576757147288629851,0731,1381,25111595.0091.0093.0086.0079.0071.0069.0061.0053.00
  Net PPE------------124128128128130132129127113200
  Goodwill2.8%1,7531,7051,7431,7231,6931,5931,6881,7821,8281,8501,888938958937918909920907925920928
  Current Liabilities-2.3%1,5371,573945909933813705737809735881752654642410396364390369414345
  Long Term Debt-0.1%5,1085,1115,6875,6905,6935,6965,9905,9936,0196,2476,4891,8531,8491,8442,0701,5771,5741,5711,5681,5651,563
    LT Debt, Current0.1%60560531.0031.0031.0031.0031.0031.0031.0031.0024924924624433.0033.0033.0033.0033.0033.0033.00
    LT Debt, Non Current-0.1%5,1085,1115,6875,6905,6935,6965,9905,9936,0196,2476,4891,8531,8491,8442,0701,5771,5741,5711,5681,5651,563
Shareholder's Equity7.1%3,7373,4893,5263,3353,0862,7453,2013,6083,9653,9384,1313,7983,6603,3773,1422,8093,1113,0542,9832,7302,757
  Retained Earnings-0.6%8798848128037349749949598308669181,2821,1601,0268787711,0681,1041,022820841
  Additional Paid-In Capital1.6%3,7003,6403,5803,5123,4773,3883,3123,2393,5353,4703,4032,6952,6342,5382,4992,2942,2662,2092,1712,1312,114
Shares Outstanding-2.0%62.0064.0064.0063.0063.0063.0062.0062.0060.0059.0059.0056.00---------
Float---7,660---9,527---10,591---5,958---7,870--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-45.5%167,339307,195296,765320,708341,971417,991303,036208,979177,755274,06041,695284,997186,271257,889182,519272,96987,798337,503148,847202,253218,096
  Share Based Compensation-5.7%52,94156,11561,43356,35261,55856,68153,68750,07053,11953,23948,16334,48531,38430,35630,60428,65425,93728,78528,28927,55226,723
Cashflow From Investing158.4%101,798-174,299-85,739-4,822-324,3784,602-89,162-37,292-10,092-26,813-5,912,370737,13273,219-279,644-741,165-60,080-159,053-159,661-2,638166,05239,992
Cashflow From Financing-27.8%-100,306-78,493-96,667-29,78819,596-289,05310,777-270,811-246,609-465,1814,664,03618,27655,878-22,656642,534-147,683-87,780-19,463-56,153-130,349-446,456
  Buy Backs34.2%99,79574,37195,594---54.00-------7,484139,053110,33519,99759,869111,249446,657

JAZZ Income Statement

2023-12-31
CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Revenues:   
Total revenues$ 3,834,204$ 3,659,374$ 3,094,238
Operating expenses:   
Cost of product sales (excluding amortization of acquired developed technologies)435,577540,517440,760
Selling, general and administrative1,343,1051,416,9671,451,683
Research and development849,658590,453505,748
Intangible asset amortization608,284599,169525,769
Acquired in-process research and development19,000444,1480
Intangible asset impairment charge0133,6480
Total operating expenses3,255,6243,724,9022,923,960
Income (loss) from operations578,580(65,528)170,278
Interest expense, net(289,438)(288,242)(278,766)
Foreign exchange gain (loss)8,787(19,014)(4,350)
Income (loss) before income tax expense (benefit) and equity in loss of investees297,929(372,784)(112,838)
Income tax expense (benefit)(119,912)(158,645)216,116
Equity in loss of investees3,0099,921714
Net income (loss)$ 414,832$ (224,060)$ (329,668)
Net income (loss) per ordinary share:   
Basic (in dollars per share)$ 6.55$ (3.58)$ (5.52)
Diluted (in dollars per share)$ 6.10$ (3.58)$ (5.52)
Weighted-average ordinary shares used in per share calculations - basic (in shares)63,29162,53959,694
Weighted-average ordinary shares used in per share calculations - diluted (in shares)72,06662,53959,694
Product sales, net   
Revenues:   
Total revenues$ 3,736,943$ 3,641,429$ 3,079,001
Royalties and contract revenues   
Revenues:   
Total revenues$ 97,261$ 17,945$ 15,237

JAZZ Balance Sheet

2023-12-31
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 1,506,310$ 881,482
Investments120,0000
Accounts receivable, net of allowances of $21,136 and $17,843 at December 31, 2023 and 2022, respectively705,794651,493
Inventories597,039714,061
Prepaid expenses185,47691,912
Other current assets320,809267,192
Total current assets3,435,4282,606,140
Property, plant and equipment, net169,646228,050
Operating lease assets65,34073,326
Intangible assets, net5,418,0395,794,437
Goodwill1,753,1301,692,662
Deferred tax assets, net477,834376,247
Deferred financing costs6,4789,254
Other non-current assets67,46455,139
Total assets11,393,35910,835,255
Current liabilities:  
Accounts payable102,75090,758
Accrued liabilities793,914803,255
Current portion of long-term debt604,95431,000
Income taxes payable35,0747,717
Deferred revenue0463
Total current liabilities1,536,692933,193
Long-term debt, less current portion5,107,9885,693,341
Operating lease liabilities, less current portion59,22571,838
Deferred tax liabilities, net847,706944,337
Other non-current liabilities104,751106,812
Commitments and contingencies (Note 14)
Shareholders’ equity:  
Ordinary shares, nominal value $0.0001 per share; 300,000 shares authorized; 62,255 and 63,214 shares issued and outstanding at December 31, 2023 and 2022, respectively66
Non-voting euro deferred shares, €0.01 par value per share; 4,000 shares authorized, issued and outstanding at both December 31, 2023 and 20225555
Capital redemption reserve473472
Additional paid-in capital3,699,9543,477,124
Accumulated other comprehensive loss(842,147)(1,125,509)
Retained earnings878,656733,586
Total shareholders’ equity3,736,9973,085,734
Total liabilities and shareholders’ equity$ 11,393,359$ 10,835,255
JAZZ
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
 CEO
 WEBSITEjazzpharma.com
 INDUSTRYBiotechnology
 EMPLOYEES2800

Jazz Pharmaceuticals PLC Frequently Asked Questions


What is the ticker symbol for Jazz Pharmaceuticals PLC? What does JAZZ stand for in stocks?

JAZZ is the stock ticker symbol of Jazz Pharmaceuticals PLC. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Jazz Pharmaceuticals PLC (JAZZ)?

As of Mon Apr 15 2024, market cap of Jazz Pharmaceuticals PLC is 6.92 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of JAZZ stock?

You can check JAZZ's fair value in chart for subscribers.

What is the fair value of JAZZ stock?

You can check JAZZ's fair value in chart for subscribers. The fair value of Jazz Pharmaceuticals PLC is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Jazz Pharmaceuticals PLC is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for JAZZ so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Jazz Pharmaceuticals PLC a good stock to buy?

The fair value guage provides a quick view whether JAZZ is over valued or under valued. Whether Jazz Pharmaceuticals PLC is cheap or expensive depends on the assumptions which impact Jazz Pharmaceuticals PLC's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for JAZZ.

What is Jazz Pharmaceuticals PLC's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, JAZZ's PE ratio (Price to Earnings) is 16.68 and Price to Sales (PS) ratio is 1.8. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. JAZZ PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Jazz Pharmaceuticals PLC's stock?

In the past 10 years, Jazz Pharmaceuticals PLC has provided -0.02 (multiply by 100 for percentage) rate of return.